Research on Nanomaterial Applications in Photothermal Therapy for Cancer

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 20 June 2024 | Viewed by 3808

Special Issue Editors


E-Mail Website
Guest Editor
Faculty of Health Sciences, University of Macau, Taipa, Macau, China
Interests: neuroimaging; cognitive aging & brain disorders; biomedical optics and optical molecular imaging
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China
Interests: design and development of polymeric genes and drug carriers as well as anti-tumor therapy, research and development of nano prodrugs and high efficiency photosensitizers and antibacterial and anti-tumor applications
Center for Cognition and Neuroergonomics, State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Zhuhai, China
Interests: intelligent drug delivery systems; multimodal imaging; cancer theranostics; nanomaterials; imaging guided therapy; ai-aided optical imaging; neuroimaging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

At present, the main clinical cancer treatments include surgical resection, chemotherapy, radiotherapy and targeted therapy, etc. But common side effects include hair loss, anorexia, nausea and vomiting greatly decreased immunity and resistance of cancer patients. In recent forty years, in order to further improve the efficacy of cancer therapy and reduce non-targeted toxicity, great efforts have been made in the research and development of new therapeutic methods such as immunotherapy, targeted therapy and photothermal therapy. Among them, a large number of studies have shown that photothermal therapy (PTT) have superior efficacy in cancer treatment, including controllable treatment process, high specificity and reactivating immune response. PTT converts absorbed light into heat energy and can high-selectively ablate tumor cells. With the rapid development of nanomaterials, research on nanomaterial applications in PTT for cancer that can high-efficiently treat malignant tumors are promising to provide a powerful strategy for cancer therapy.

We are pleased to invite you (to contribute to this Special Issue with topic “research on nanomaterial applications in photothermal therapy for cancer”.)

Near-infrared photothermal therapy has a broad application prospect in the treatment of solid tumors by virtue of its advantages such as controllable time and space, high selectivity and few side effects. However, there are three main bottlenecks at present: First, local overheating caused by laser induced nonspecific heating and heat diffusion of pure photothermal therapy may damage normal tissues and cells around the target and perforate tissues, making real-time temperature feedback in the treatment process an urgent need. Second, tumor residue after photothermal therapy is often located at the edge of the focus or even in the systemic blood circulation. Pure photothermal therapy is difficult to completely ablate solid tumors, so it needs to be combined with other therapies such as immunotherapy to inhibit metastasis and recurrence. Third, the current photothermal treatment mainly focuses on the near-infrared region I (700-900 nm) with limited penetration depth. Comparatively, the deeper tissue penetration ability and higher signal-to-noise ratio of the near-infrared region II (1000-1700 nm) are more conducive to the realization of accurate photothermal treatment. Therefore, it is important for this Special Issue to highlight research on nanomaterial applications in photothermal therapy for cancer that aimed to address these three main bottlenecks and other relative creative works.

This Special Issue aims to (highlight current progress in the research on nanomaterial applications in photothermal therapy for cancer).

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following:

  • Nanomaterials
  • Drug delivery
  • Photothermal Therapy
  • Photothermal immunotherapy
  • Cancer Treatment
  • Immunogenic cell death
  • Laser therapy
  • Cancer theranostics
  • Photothermal conversion efficiency
  • Tumor targeting
  • Hypothermic photothermal therapy
  • Combined treatment
  • Imaging guided therapy
  • Heat shock protein inhibition
  • Time domain modeling and simulation of photothermal therapy
  • Thermal diffusion modeling
  • Thermal diffusion control

We look forward to receiving your contributions.

Prof. Dr. Zhen Yuan
Dr. Zhaopei Guo
Dr. Mengze Xu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomaterials
  • drug delivery
  • photothermal therapy
  • photothermal immunotherapy
  • cancer treatment
  • immunogenic cell death
  • laser therapy
  • cancer theranostics
  • photothermal conversion efficiency
  • tumor targeting

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 4909 KiB  
Article
High-Performance Hybrid Phototheranostics for NIR-IIb Fluorescence Imaging and NIR-II-Excitable Photothermal Therapy
by Qi Wang, Xinmin Zhang, Youguang Tang, Yanwei Xiong, Xu Wang, Chunlai Li, Tangxin Xiao, Feng Lu and Mengze Xu
Pharmaceutics 2023, 15(8), 2027; https://doi.org/10.3390/pharmaceutics15082027 - 27 Jul 2023
Cited by 1 | Viewed by 1457
Abstract
Photothermal therapy operated in the second near-infrared (NIR-II, 1000–1700 nm) window and fluorescence imaging in the NIR-IIb (1500–1700 nm) region have become the most promising techniques in phototheranostics. Their combination enables simultaneous high-resolution optical imaging and deep-penetrating phototherapy, which is essential for high-performance [...] Read more.
Photothermal therapy operated in the second near-infrared (NIR-II, 1000–1700 nm) window and fluorescence imaging in the NIR-IIb (1500–1700 nm) region have become the most promising techniques in phototheranostics. Their combination enables simultaneous high-resolution optical imaging and deep-penetrating phototherapy, which is essential for high-performance phototheranostics. Herein, carboxyl-functionalized small organic photothermal molecules (Se-TC) and multi-layered NIR-IIb emissive rare-earth-doped nanoparticles (NaYF4:Yb,Er,Ce@NaYF4:Yb,Nd@NaYF4, RENP) were rationally designed and successfully synthesized. Then, high-performance hybrid phototheranostic nanoagents (Se-TC@RENP@F) were easily constructed through the coordination between Se-TC and RENP and followed by subsequent F127 encapsulation. The carboxyl groups of Se-TC can offer strong binding affinity towards rare-earth-doped nanoparticles, which help improving the stability of Se-TC@RENP@F. The multilayered structure of RENP largely enhance the NIR-IIb emission under 808 nm excitation. The obtained Se-TC@RENP@F exhibited high 1064 nm absorption (extinction coefficient: 24.7 L g−1 cm−1), large photothermal conversion efficiency (PCE, 36.9%), good NIR-IIb emission (peak: 1545 nm), as well as great photostability. Upon 1064 nm laser irradiation, high hyperthermia can be achieved to kill tumor cells efficiently. In addition, based on the excellent NIR-IIb emission of Se-TC@RENP@F, in vivo angiography and tumor detection can be realized. This work provides a distinguished paradigm for NIR-IIb-imaging-guided NIR-II photothermal therapy and establishes an artful strategy for high-performance phototheranostics. Full article
Show Figures

Figure 1

16 pages, 23082 KiB  
Article
Biomimetic Theranostic Agents with Superior NIR-II Photoacoustic and Magnetic Resonance Imaging Performance for Targeted Photothermal Therapy of Prostate Cancer
by Ling Liu, Shangpo Yang, Ziliang Zheng, Qingshuang Li, Chenchen Liu, Dehong Hu, Zhou Liu, Xiaoping Zhang, Ruiping Zhang and Duyang Gao
Pharmaceutics 2023, 15(6), 1617; https://doi.org/10.3390/pharmaceutics15061617 - 30 May 2023
Cited by 4 | Viewed by 1712
Abstract
The accurate diagnosis and treatment of prostate cancer at an early stage is crucial to reduce mortality rates. However, the limited availability of theranostic agents with active tumor-targeting abilities hinders imaging sensitivity and therapeutic efficiency. To address this challenge, we have developed biomimetic [...] Read more.
The accurate diagnosis and treatment of prostate cancer at an early stage is crucial to reduce mortality rates. However, the limited availability of theranostic agents with active tumor-targeting abilities hinders imaging sensitivity and therapeutic efficiency. To address this challenge, we have developed biomimetic cell membrane-modified Fe2O3 nanoclusters implanted in polypyrrole (CM-LFPP), achieving photoacoustic/magnetic resonance dual-modal imaging-guided photothermal therapy of prostate cancer. The CM-LFPP exhibits strong absorption in the second near-infrared window (NIR-II, 1000–1700 nm), showing high photothermal conversion efficiency of up to 78.7% under 1064 nm laser irradiation, excellent photoacoustic imaging capabilities, and good magnetic resonance imaging ability with a T2 relaxivity of up to 48.7 s−1 mM−1. Furthermore, the lipid encapsulation and biomimetic cell membrane modification enable CM-LFPP to actively target tumors, leading to a high signal-to-background ratio of ~30.2 for NIR-II photoacoustic imaging. Moreover, the biocompatible CM-LFPP enables low-dose (0.6 W cm−2) photothermal therapy of tumors under 1064 nm laser irradiation. This technology offers a promising theranostic agent with remarkable photothermal conversion efficiency in the NIR-II window, providing highly sensitive photoacoustic/magnetic resonance imaging-guided prostate cancer therapy. Full article
Show Figures

Figure 1

Back to TopTop